Progesterone treatment to prevent preterm birth

Clinical Obstetrics and Gynecology

Volumn 47, Issue 4, 2004, Pages 784-795

  Meis, Paul J ^a   Connors, Ngina ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTRIOL; ESTROGEN; GESTAGEN; HYDROCORTISONE; HYDROXYPROGESTERONE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NITRIC OXIDE; NORETHISTERONE; PRASTERONE SULFATE; PROGESTERONE; PROGESTERONE RECEPTOR; PROSTAGLANDIN; RITODRINE;

CELLULAR IMMUNITY; CHILDBIRTH; CLINICAL TRIAL; DRUG BIOAVAILABILITY; GAP JUNCTION; GESTATION PERIOD; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; NONHUMAN; PREGNANCY; PREMATURE LABOR; PROGESTERONE RELEASE; REVIEW; TOCOLYSIS; UTERUS CONTRACTILITY;

FEMALE; HUMANS; PREGNANCY; PREMATURE BIRTH; PROGESTERONE; RANDOMIZED CONTROLLED TRIALS;

EID: 7744225551     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.grf.0000141452.68933.44     Document Type: Review

References (39)

1. Mattison DR, Damus K, Fiore E, et al. Preterm delivery: a public health perspective. Paediatr Perinat Epidemiol. 2001;15(suppl 2):7-16.
2. Csapo AI, Pohanka O, Kaihola HL. Progesterone deficiency and premature labour. Br Med J. 1974;1:137-140.
3. Csapo AI. Progesterone "block". Am J Anat. 1956;98:273-291.
4. Mazor M, Hershkovitz R, Chaim W, et al. Human preterm birth is associated with systemic and local changes in progesterone/17β-estradiol ratios. Am J Obstet Gynecol. 1994;171:231-236.
5. Romero R, Scoccia B, Mazor M, et al. Evidence for a local change in the progesterone/estrogen ratio in human parturition at term. Am J Obstet Gynecol. 1988;159:657-660.
6. Stanczyk FZ. Pharmacokinetics of progesterone administered by the oral and parenteral routes. J Reprod Med. 1999;44:141-147.
7. Tulchinsky D. Sources of plasma 17α-hydroxyprogesterone in human pregnancy. J Clin Endocrinol Metab. 1972;35:799-808.
8. Reifenstein E. Introduction of marked as well as prolonged biologic activity by esterification. Fertil Steril. 1957;8:50-79.
9. Tibbetts TA, Conneely OM, O'Malley BW. Progesterone via its receptor antagonizes the pro-inflammatory activity of estrogen in the mouse uterus. Biol Reprod. 1999;60:1158-1165.
10. Granger DK, Domenick M, Ildstad ST. Transplantation immunology and immunosuppression. In: Townsend CM Jr, ed. Sabiston Textbook of Surgery. 16th ed. Philadelphia, PA: W. B. Saunders; 2001.
11. Szekeres-Bartho J, Barakonyi A, Par G, et al. Progesterone as an immunomodulatory molecule. Int J Immunopharmacol. 2001;1:1037-1048.
12. Laskarin G, Tokmadzic VS, Strbo N, et al. Progesterone induced blocking factor mediates progesterone induced suppression of decidual lymphocyte cytotoxicity. Am J Reprod Immunol. 2002;48:201-209.
13. Bamberger CM, Else T, Bamberger A, et al. Dissociative glucocorticoid activity of medroxyprogesterone acetate in normal human lymphocytes. J Clin Endocrinol Metab. 1999;84:4055-4061.
14. Rauk PN, Chiao JP. Interleukin-1 stimulates human uterine prostaglandin production through induction of cyclooxygenase-2 expression. Am J Reprod Immunol. 2000;43:152-159.
15. Elovitz M, Wang Z. Medroxyprogesterone acetate, but not progesterone, protects against inflammation-induced parturition and intrauterine fetal demise. Am J Obstet Gynecol. 2004;190:693-701.
16. Kurz C, Tempfer CB, Boecskoer S, et al. The PROGINS progesterone receptor gene polymorphism and idiopathic recurrent miscarriage. J Soc Gynecol Investig. 2001;8:295-298.
17. Haluska GJ, Wells TR, Hirst JJ, et al. Progesterone receptor localization and isoforms in myometrium, decidua, and fetal membranes from rhesus macaques: evidence for functional progesterone withdrawal at parturition. J Soc Gynecol Investig. 2002;9:125-136.
18. How H, Huang Z-H, Zuo J, et al. Myometrial estradiol and progesterone receptor changes in preterm and term pregnancies. Obstet Gynecol. 1995;86:936-940.
19. Henderson D, Wilson T. Reduced binding of progesterone receptor to its nuclear response element after human labor onset. Am J Obstet Gynecol. 2001;185:579-585.
20. Mesiano S, Chan E, Fitter JT, et al. Progesterone withdrawal and estrogen activation in human parturition are coordinated by progesterone receptor A expression in the myometrium. J Clin Endocrinol Metab. 2002;87:2924-2930.
21. Chow L, Lye S. Expression of the gap junction protein connexin-43 is increased in the human myometrium toward term and with the onset of labor. Am J Obstet Gynecol. 1994;170:788-795.
22. Garfield RE, Saade G, Buhimschi C, et al. Control and assessment of the uterus and cervix during pregnancy and labor. Hum Reprod Update. 1998;4:673-695.
23. Papiernik E. Double blind study of an agent to prevent pre-term delivery among women at increased risk. In Edition Schering, Serie IV, fiche 3. 1970:65-68.
24. Johnson JWC, Austin KL, Jones GS, et al. Efficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med. 1975;292:675-680.
25. Johnson JWC, Lee PA, Zachary AS, et al. High-risk prematurity - progestin treatment and steroid studies. Obstet Gynecol. 1979; 54:412-418.
26. Yemini M, Borenstein R, Dreazen E, et al. Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 1985;151:574-577.
27. Hartikainen-Sorri A-L, Kauppila A, Tuimala R. Inefficacy of 17 alpha hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstet Gynecol. 1980;56:692.
28. Hauth JC, Gilstrap LC, Brekken AL, et al. The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population. Am J Obstet Gynecol. 1983;146:187-190.
29. Goldstein P, Berrier J, Rosen S, et al. A meta-analysis of randomized control trials of progestational agents in pregnancy. Br J Obstet Gynecol. 1989;96:265-274.
30. Keirse MJNC. Progesterone administration in pregnancy may prevent pre-term delivery. Br J Obstet Gynecol. 1990;97:149-154.
31. Hobel CJ, Ross MG, Bemis RL, et al. The West Los Angeles Preterm Birth Prevention Project. I. Program impact on high-risk women. Am J Obstet Gynecol. 1994;170:54-62.
32. da Fonseca EB, Bittar RE, Carvalho MHB, et al. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2003;188:419-424.
33. da Fonseca EB. Response to letter to the editor. Am J Obstet Gynecol. 2004;190:1803.
34. Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348:2379-2385.
35. Fuchs F, Stademann G. Treatment of threatened premature labor with large doses of progesterone. Am J Obstet Gynecol. 1960;79:172-176.
36. Kaupilla A, Hartikainen-Sorri A-L, Olli J, et al. Suppression of threatened premature labor by administration of cortisol and 17 alpha-hydroxyprogesterone caporate: A comparison with ritodrine. Am J Obstet Gynecol. 1980;138:404-408.
37. Erny R, Pigne C, Prouvost M, et al. The effects of oral administration of progesterone for premature labor. Am J Obstet Gynecol. 1986;154:525-529.
38. Noblott G, Audra P, Dargent D, et al. The use of micronized progesterone in the treatment of menace of preterm delivery. Eur J Obstet Gynecol Reprod Biol. 1991;40:203-209.
39. Brenner WB, Hendricks CH. Effect of medroxyprogesterone acetate upon the duration and characteristics of human gestation and labor. Am J Obstet Gynecol. 83:1094-1098.